{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092025","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2026-08-06T20:16:17+00:00","discovered_at":"2026-08-06T20:18:00.324379+00:00","generated_at":"2026-08-06T20:20:00.595168+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NextCure Q2 net loss $14.9M; proposes all-stock merger with Avere Therapeutics","bullets":["Definitive all-stock merger with Avere Therapeutics; combined co to trade as AVRX; concurrent $320M private financing.","Cash, equivalents, and marketable securities $20.1M at June 30, 2026, down from $41.8M at Dec 31, 2025.","Net loss $14.9M for Q2 2026 vs $26.8M for Q2 2025; R&D expenses fell to $7.4M from $24.1M.","Asset impairment costs of $5.1M from restructuring initiatives to reduce footprint and sell assets.","LigaChem elected to continue LNCB74 development; NextCure eligible for future milestones and royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092025","json":"https://secwatch.observer/filing/0001104659-26-092025.json","markdown":"https://secwatch.observer/filing/0001104659-26-092025.md","text":"https://secwatch.observer/filing/0001104659-26-092025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/0001104659-26-092025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:20:00.595168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}